Stripe never went public — now it and Advent International are bidding $53 billion ($60.50/share, a 28% premium) to take PayPal private. The real prize: Venmo.
Vera Therapeutics just won FDA accelerated approval for TRUTAKNA, the first dual BAFF/APRIL inhibitor for IgA nephropathy — priced at $425,000 a year. Here's why the two-target bet matters.
The AI chip company Cerebras Systems — the most prominent challenger to Nvidia's GPU empire — hit the Nasdaq on Thursday under the ticker CBRS and...
> In 2025, startups discovered AI. In 2026, the winners figured out which tools to use and when. Here's the stack the smartest founders are runni...
On May 12, a Jacksonville startup called Star Catcher Industries closed a $65 million Series A round to build what it describes as "the first power gr...
Helsing just closed a $1.8B Series E at an $18B valuation — Europe's biggest-ever defense-startup round, and the cap table was oversubscribed.
🔥 Gigabyte Just Dropped a $400 WOLED Gaming Monitor and It Changes Everything...
The AI chip company Cerebras Systems — the most prominent challenger to Nvidia's GPU empire — hit the Nasdaq on Thursday under the ticker CBRS and...
> In 2025, startups discovered AI. In 2026, the winners figured out which tools to use and when. Here's the stack the smartest founders are runni...
Developer documentation is the silent killer of product adoption. A 2025 study by the Developer Marketing Alliance found that 67% of developers will a...
Vera Therapeutics just won FDA accelerated approval for TRUTAKNA, the first dual BAFF/APRIL inhibitor for IgA nephropathy — priced at $425,000 a year. Here's why the two-target bet matters.
Feature Image: https://images.unsplash.com/photo-1648792940059-3b782a7b8b20?crop=entropy&cs=tinysrgb&fit=max&fm=jpg&ixid=M3w3ODQzODd8MHwxfHNlYXJj...
BREAKING NEWS — In a move that signals the pharmaceutical industry's full-scale embrace of artificial intelligence, Swiss healthcare giant Roche has ...
